Can The Rally Continue In Biotech?

biotechnologyMitchell Clark: The last time we looked at Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), the position was trading around $121.00 a share. Now, it’s $175.00 a share, and once again, the company reported outstanding financial results from its “Soliris” wonder-drug.

This stock has been a powerhouse wealth creator, and virtually every time we take a look at it, the share price is higher.

There has been and continues to be tremendous momentum with biotechnology stocks in this market. And a great deal of it is happening in the large-cap space, where price momentum, thanks to institutional investors, has been robust and often very consistent.

Previously in these pages when looking at Alexion Pharmaceuticals, we also considered Biogen Idec Inc. (NASDAQ:BIIB). (See “How Risk-Averse Investors Can Capitalize on 2014’s Expected Record Drug Approvals.”) It’s a similar story in terms of the price momentum being experienced on the stock market. In our last update, the position was treading around $290.00 a share; now, it’s $325.00, representing another new record-high.

Strong trading action in biotechnology stocks is partially due to economic success within this specific sector, but it’s also a reflection of buoyant capital markets, or equities in particular. The speculative fervor that investors have for this sector has been unmatched in recent history.

The NASDAQ Biotechnology Index broke out of a 12-year price consolidation in 2011 and has almost tripled since. While there were some retrenchments in this index in the last few years, considering the inherent volatility in biotechnology stocks, the pullbacks have been minimal.

While monetary policy is favorable to equities, like it is currently, I’d say there’s further price momentum in a lot of these stocks, specifically those that are already existing winners.

Momentum investing is risky business, and it requires the rest of the marketplace to be buoyant. But investors have proven to go where the growth is, and it certainly is with this specific sector.

In good markets, buying high to sell higher is very much a useful investment strategy. The key is to know when to get out of that kind of trading.

(...)Click here to continue reading the original article: Can The Rally Continue In Biotech? [Alexion Pharmaceuticals, Inc., Biogen Idec Inc, Amgen, Inc.]

You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks